{"id":189556,"date":"2025-11-19T20:18:06","date_gmt":"2025-11-19T20:18:06","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/189556\/"},"modified":"2025-11-19T20:18:06","modified_gmt":"2025-11-19T20:18:06","slug":"abbott-is-weighing-takeover-of-exact-sciences-bloomberg-news-reports","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/189556\/","title":{"rendered":"Abbott is weighing takeover of Exact Sciences, Bloomberg News reports"},"content":{"rendered":"<p>Nov 19 (Reuters) &#8211; Medical device maker Abbott Laboratories <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/ABT.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(ABT.N), opens new tab<\/a> is nearing a potential takeover of cancer test maker Exact Sciences Corp <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/EXAS.O\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(EXAS.O), opens new tab<\/a>, Bloomberg News reported on Wednesday, citing people familiar with the matter.<\/p>\n<p>The deal could be announced in the coming days and deliberations are ongoing, which could still be delayed or falter, the report added.<\/p>\n<p data-testid=\"promo-box\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__promo-box__hVl8h\"> Sign up  <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/abbott-is-weighing-takeover-exact-sciences-bloomberg-news-reports-2025-11-19\/undefined?location=article-paragraph&amp;redirectUrl=%2Fbusiness%2Fhealthcare-pharmaceuticals%2Fabbott-is-weighing-takeover-exact-sciences-bloomberg-news-reports-2025-11-19%2F\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p>Shares of Exact Sciences, which has a market value of more than $13 billion, rose nearly 25%, while Abbott&#8217;s shares fell 3% in afternoon trading.<\/p>\n<p>Abbott is discussing the terms of a transaction, the report said.<\/p>\n<p>The companies did not immediately respond to Reuters&#8217; requests for comment.<\/p>\n<p>Exact Sciences&#8217; flagship diagnostic test, Cologuard, is a non-invasive test to screen for colorectal cancer, providing a convenient alternative compared to a colonoscopy.<\/p>\n<p>Unlike a colonoscopy, which requires bowel preparation, sedation and a clinical visit, Exact&#8217;s test can be done at home by collecting a stool sample and mailing it to a lab.<\/p>\n<p>Colorectal cancer is the second leading cause of cancer-related deaths worldwide, according to WHO data.<\/p>\n<p data-testid=\"SignOff\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__full_width__kCIGb body-module__extra_small_body__Bfz20 sign-off-module__text__LQAMP\">Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Alan Barona<\/p>\n<p data-testid=\"Body\" dir=\"ltr\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__element__5eCce article-body-module__trust-badge__5mS3f\">Our Standards: <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.thomsonreuters.com\/en\/about-us\/trust-principles.html\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__medium__2Rl30 text-module__small__sph8i link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n<p><a href=\"https:\/\/www.reutersagency.com\/en\/licensereuterscontent\/?utm_medium=rcom-article-media&amp;utm_campaign=rcom-rcp-lead\" target=\"_blank\" dir=\"ltr\" class=\"button-module__link__A3sD0 button-module__secondary__70gBu button-module__round__QDFgq button-module__w_auto__Sem-F\" data-testid=\"LicenceContentButton\" rel=\"nofollow noopener\">Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Nov 19 (Reuters) &#8211; Medical device maker Abbott Laboratories (ABT.N), opens new tab is nearing a potential takeover&hellip;\n","protected":false},"author":2,"featured_media":189557,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[82519,82499,106025,36586,82500,82502,87219,18,135,475,474,87211,87212,87651,106026,19,17,106027,106028,96155,82506,82524,88229,82510,106024,87204,84457,87203,82533,107],"class_list":{"0":"post-189556","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-amers","9":"tag-bact","10":"tag-biodt","11":"tag-biz","12":"tag-cmpny","13":"tag-deal1","14":"tag-destoushem","15":"tag-eire","16":"tag-health","17":"tag-health-care","18":"tag-healthcare","19":"tag-heca","20":"tag-hlthse","21":"tag-hot","22":"tag-hprd","23":"tag-ie","24":"tag-ireland","25":"tag-medq","26":"tag-medq1","27":"tag-mrch","28":"tag-mrg","29":"tag-namer","30":"tag-phmr","31":"tag-publ","32":"tag-rhpimedtech","33":"tag-rhpimergers-acquisitions","34":"tag-stx","35":"tag-topicpharma-healthcare-business-health","36":"tag-topnws","37":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115578215000134150","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/189556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=189556"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/189556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/189557"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=189556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=189556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=189556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}